This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Bradykinin B1 receptor (BDKRB1; B1R)	An *in vitro* and mouse study identified cyclic peptide–based B1R antagonists that could help treat pain. The antagonists were created by linking known peptide inhibitors of B1R to kalata B1, an orally available cysteine-rich plant peptide with a cyclic backbone. In a mouse model of visceral pain, oral dosing of the new antagonists decreased pain compared with dosing of the linear parent peptides. Next steps include determining the bioavailability of the new inhibitors in small animals. Evotec AG has a B1R antagonist in preclinical development for pain and inflammation. *SciBX* 5(20); doi:10.1038/scibx.2012.527 Published online May 17, 2012	Patent application filed; available for licensing	Wong, C.T.T. *et al. Angew. Chem. Int. Ed.*; published online April 24, 2012; doi:10.1002/anie.201200984 **Contact:** James P. Tam, Nanyang Technological University, Singapore, Singapore e-mail: jptam@ntu.edu.sg